Oct 28, 2026, 4:39 PMGovernment Regulation
Trump Administration Won’t Act Against Pharmacies Compounding BPC-157, TB-500
The Trump administration says the government will not act against compounding pharmacies making six popular wellness products, including BPC-157 and TB-500.
Listen to this briefingAudio briefing
Summary
On October 28, 2026, MarketWatch reported that the Trump administration said the government would not take action against compounding pharmacies producing six popular wellness products. BPC-157 and TB-500 were the only products identified in the available feed summary, and the stated nonaction clears the way for their production.
Only a short feed summary was available. It did not identify the other four products, the responsible government agency, the policy vehicle, its effective date, eligibility conditions or any next procedural step, leaving the measure’s scope unspecified.
Positives
- Government nonaction covers six popular wellness products made by compounding pharmacies.
- BPC-157 is specifically included among the products whose compounded production will not draw government action.
- TB-500 receives the same stated treatment, clearing a path for compounding pharmacies to produce it.
Risks & concerns
- The available source is only a short MarketWatch feed summary, with no full article details.
- Four of the six covered wellness products are not identified in the summary.
- The summary does not name the government agency, policy vehicle, effective date, conditions or next procedural step.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/trump-administration-clears-the-way-for-production-of-peptides-like-bpc-157-and-tb-500-28ac2d11?mod=mw_rss_topstories
Read full article
